Your browser doesn't support javascript.
loading
Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study.
Marijon, Eloi; Leclercq, Christophe; Narayanan, Kumar; Boveda, Serge; Klug, Didier; Lacaze-Gadonneix, Jonathan; Defaye, Pascal; Jacob, Sophie; Piot, Olivier; Deharo, Jean-Claude; Perier, Marie-Cecile; Mulak, Genevieve; Hermida, Jean-Sylvain; Milliez, Paul; Gras, Daniel; Cesari, Olivier; Hidden-Lucet, Françoise; Anselme, Frederic; Chevalier, Philippe; Maury, Philippe; Sadoul, Nicolas; Bordachar, Pierre; Cazeau, Serge; Chauvin, Michel; Empana, Jean-Philippe; Jouven, Xavier; Daubert, Jean-Claude; Le Heuzey, Jean-Yves.
Afiliação
  • Marijon E; Cardiology Department, European Georges Pompidou Hospital, Paris, France Paris Descartes University, Paris, France Paris Cardiovascular Research Centre, Paris, France.
  • Leclercq C; Pontchaillou University Hospital and INSERM 1099, CIC-IT 804 Rennes, France.
  • Narayanan K; Paris Cardiovascular Research Centre, Paris, France.
  • Boveda S; Clinique Pasteur, Toulouse, France.
  • Klug D; Lille University Hospital and University of Lille, Lille, France.
  • Lacaze-Gadonneix J; Cardiology Department, European Georges Pompidou Hospital, Paris, France Paris Descartes University, Paris, France.
  • Defaye P; Arrhythmia Department, University Hospital, Grenoble, France.
  • Jacob S; Epidemiology Unit, IRSN, Paris, France.
  • Piot O; Centre Cardiologique du Nord, Saint Denis, France.
  • Deharo JC; Cardiology Division, Hôpital La Timone, Marseille, France.
  • Perier MC; Paris Cardiovascular Research Centre, Paris, France.
  • Mulak G; French Society of Cardiology, Paris, France.
  • Hermida JS; Amiens University Hospital, Amiens, France.
  • Milliez P; Caen University Hospital, Caen, France.
  • Gras D; Nouvelles Cliniques Nantaises, Nantes, France.
  • Cesari O; Clinique Saint Gatien, Tours, France.
  • Hidden-Lucet F; Cardiology Department, La Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
  • Anselme F; Cardiology Division, Rouen University Hospital, Rouen, France.
  • Chevalier P; East Lyon School of Medicine, Louis Pradel Hospital, Bron, France.
  • Maury P; Cardiology Division, Rangueil University Hospital, Toulouse, France.
  • Sadoul N; Cardiology Division, Nancy University Hospital, Nancy, France.
  • Bordachar P; Haut-Lévêque Hospital, Bordeaux, France.
  • Cazeau S; Saint Joseph Hospital, Paris, France.
  • Chauvin M; Strasbourg University Hospital, Strasbourg, France.
  • Empana JP; Paris Cardiovascular Research Centre, Paris, France.
  • Jouven X; Cardiology Department, European Georges Pompidou Hospital, Paris, France Paris Descartes University, Paris, France Paris Cardiovascular Research Centre, Paris, France.
  • Daubert JC; Pontchaillou University Hospital and INSERM 1099, CIC-IT 804 Rennes, France.
  • Le Heuzey JY; Cardiology Department, European Georges Pompidou Hospital, Paris, France Paris Descartes University, Paris, France Paris Cardiovascular Research Centre, Paris, France jean-yves.le-heuzey@egp.aphp.fr.
Eur Heart J ; 36(41): 2767-76, 2015 Nov 01.
Article em En | MEDLINE | ID: mdl-26330420
ABSTRACT

AIMS:

The choice of resynchronization therapy between with (CRT-D) and without (CRT-P) a defibrillator remains a contentious issue. Cause-of-death analysis among CRT-P, compared with CRT-D, patients could help evaluate the extent to which CRT-P patients would have additionally benefited from a defibrillator in a daily clinical practice. METHODS AND

RESULTS:

A total of 1705 consecutive patients implanted with a CRT (CRT-P 535 and CRT-D 1170) between 2008 and 2010 were enrolled in CeRtiTuDe, a multicentric prospective follow-up cohort study, with specific adjudication for causes of death at 2 years. Patients with CRT-P compared with CRT-D were older (P < 0.0001), less often male (P < 0.0001), more symptomatic (P = 0.0005), with less coronary artery disease (P = 0.003), wider QRS (P = 0.002), more atrial fibrillation (P < 0.0001), and more co-morbidities (P = 0.04). At 2-year follow-up, the annual overall mortality rate was 83.80 [95% confidence interval (CI) 73.41-94.19] per 1000 person-years. The crude mortality rate among CRT-P patients was double compared with CRT-D (relative risk 2.01, 95% CI 1.56-2.58). In a Cox proportional hazards regression analysis, CRT-P remained associated with increased mortality (hazard ratio 1.54, 95% CI 1.07-2.21, P = 0.0209), although other potential confounders may persist. By cause-of-death analysis, 95% of the excess mortality among CRT-P subjects was related to an increase in non-sudden death.

CONCLUSION:

When compared with CRT-D patients, excess mortality in CRT-P recipients was mainly due to non-sudden death. Our findings suggest that CRT-P patients, as currently selected in routine clinical practice, would not potentially benefit with the addition of a defibrillator.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia de Ressincronização Cardíaca / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia de Ressincronização Cardíaca / Insuficiência Cardíaca Tipo de estudo: Clinical_trials / Etiology_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article